v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Statement of Comprehensive Income [Abstract]        
Net income before allocation to noncontrolling interests $ 8,623 $ 8,159 $ 26,404 $ 18,633
Foreign currency translation adjustments, net (918) (866) (2,549) (366)
Unrealized holding gains/(losses) on derivative financial instruments, net 589 213 1,443 179
Reclassification adjustments for (gains)/losses included in net income [1] (615) 48 (972) 286
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total (26) 261 471 464
Unrealized holding gains/(losses) on available-for-sale securities, net (777) (266) (1,397) (128)
Reclassification adjustments for (gains)/losses included in net income [2] 606 9 1,094 (172)
Other comprehensive income (loss), available-for-sale securities, before tax, total (171) (257) (303) (300)
Reclassification adjustments related to amortization of prior service costs and other, net (31) (39) (99) (119)
Reclassification adjustments related to curtailments of prior service costs and other, net 2 (58) (8) (62)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax (29) (97) (107) (181)
Other comprehensive income/(loss), before tax (1,144) (959) (2,488) (382)
Tax provision/(benefit) on other comprehensive income/(loss) (33) (65) (149) (44)
Other comprehensive income/(loss) before allocation to noncontrolling interests (1,111) (894) (2,339) (338)
Comprehensive income/(loss) before allocation to noncontrolling interests 7,512 7,265 24,065 18,296
Less: Comprehensive income/(loss) attributable to noncontrolling interests 10 9 16 48
Comprehensive income/(loss) attributable to Pfizer Inc. $ 7,503 $ 7,256 $ 24,049 $ 18,248
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2] Reclassified into Other (income)/deductions—net.